Heuschnupfenspray

Heuschnupfenspray is a nasal spray that contains the corticosteroid Mometasone furoate (Ph. Eur.) at a pharmaceutical‑grade strength, formulated for intranasal administration. It is marketed in the European Union and is intended for the local treatment of nasal symptoms associated with allergic rhinitis. The product delivers a measured dose of the active ingredient directly to the nasal mucosa to help control inflammation.

Heuschnupfenspray is indicated for the relief of nasal symptoms caused by allergic rhinitis, including both seasonal and perennial forms. It is used to reduce congestion, sneezing, itching, and rhinorrhea associated with hay fever and other allergic triggers.

- Seasonal allergic rhinitis (hay fever) - Perennial allergic rhinitis - Nasal congestion due to allergic inflammation - Sneezing and nasal itching caused by allergens - Relief of rhinorrhea in allergic conditions

Adverse reactions to Heuschnupfenspray are generally mild to moderate, but serious events can occur, especially with prolonged use.

Common: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleeds) - Throat irritation or dryness - Altered taste or smell - Cough

Serious: - Nasal septum perforation - Severe or persistent nosebleeds - Vision changes (e.g., cataracts, glaucoma) - Adrenal suppression with systemic effects - Anaphylactic or severe allergic reactions

Before using Heuschnupfenspray, consider the following safety points to minimize risks.

- Do not use if you have an active nasal infection or recent nasal surgery without medical advice. - Use caution during pregnancy or lactation; discuss risks with a healthcare professional. - Limit duration of continuous use unless directed by a physician to avoid systemic corticosteroid exposure. - Monitor for signs of adrenal insufficiency or unusual bruising. - Keep the spray tip clean and avoid sharing the device with others. - Store at room temperature, protected from moisture and heat.

Heuschnupfenspray may interact with other medications or substances that affect corticosteroid activity or nasal physiology.

Avoid: - Concurrent systemic corticosteroids unless prescribed, as this may increase systemic exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that could raise local drug levels.

Use with caution: - Other intranasal steroids or decongestants, which may increase local irritation. - Antihistamines, which can be combined but should be monitored for additive sedation. - Live vaccines, as immunosuppression could affect vaccine response. - Herbal supplements with corticosteroid‑like activity (e.g., licorice root).